Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 6/20 | 0.36 |
| ▸ | ITGA2 | P17301 | 6/20 | 0.36 |
| ▸ | CTSL | P07711 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878041 | 1.00 | ITGB1 (0.36) | ITGB1ITGA2CTSL | |
| SCHEMBL4878472 | 0.66 | BACE1 (0.46) | ITGB1ITGA2 | |
| SCHEMBL8857195 | 0.55 | GRM2 (0.58) | — | |
| SCHEMBL4872651 | 0.55 | ITGB1 (0.41) | ITGB1ITGA2 | |
| SCHEMBL4872647 | 0.55 | ITGB1 (0.41) | ITGB1ITGA2 | |
| SCHEMBL31312684 | 0.52 | USP2 (0.40) | — | |
| SCHEMBL22772814 | 0.52 | NR1H2 (0.36) | — | |
| SCHEMBL31446045 | 0.52 | HTR2A (0.39) | — | |
| SCHEMBL31224635 | 0.51 | HSP90AA1 (0.36) | — | |
| SCHEMBL31224242 | 0.51 | HSP90AA1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | ITGB1 3026/4885ITGA2 4036/4885CTSL 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.